证券代码：600587 证券简称：新华医疗 公告编号：临 2025-066 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近日 收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况 如下： 山东新华医疗器械股份有限公司 一、医疗器械注册证的具体情况 （一）白介素 6 检测试剂盒（量子点荧光免疫层析法） 1、产品名称：白介素 6 检测试剂盒（量子点荧光免疫层析法） 2、注册证编号：鲁械注准 20252400784 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博高新区齐祥路 3588 号 6、结构及组成：试剂盒由检测试剂卡、检测缓冲液和 IC 卡（二维码）组成。 测试卡由试剂条与塑料卡盒组成，其中试剂条由硝酸纤维素膜（包被有白介素 6 抗体和鸡 IgY）、结合垫（含有量子点荧光标记白介素 6 抗体和量子点荧光标记羊 抗鸡 ...

人民财讯12月29日电，新华医疗（600587）12月29日公告，公司于近日收到山东省药品监督管理局颁发 的《中华人民共和国医疗器械注册证》，产品分别为：白介素6检测试剂盒(量子点荧光免疫层析法)和 降钙素原/白介素6二联检测试剂盒(量子点荧光免疫层析法)。 ...

新华医疗公告称，近日收到山东省药监局颁发的两款《中华人民共和国医疗器械注册证》，分别为白介 素6检测试剂盒和降钙素原/白介素6二联检测试剂盒，批准日期均为2025年12月24日，有效期至2030年 12月23日。截至目前，国内同行业约500家公司已取得同类产品注册证。两款产品丰富了公司体外诊断 产品线，利于提升竞争力，但产品上市后销售情况取决于市场推广，暂无法预测对业绩的具体影响。 ...

证券代码：600587 证券简称：新华医疗 公告编号：临2025-065 山东新华医疗器械股份有限公司 关于公司产品获得三类和二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）及全资子公司山东新华血液技术有限 公司于近日收到国家药品监督管理局和山东省药品监督管理局颁发的《中华人民共和国医疗器械注册 证》，具体情况如下： 一、医疗器械注册证的具体情况 （一）血液透析器 1、产品名称：血液透析器 2、注册证编号：国械注准20253102637 3、注册人名称：山东新华血液技术有限公司 4、注册人住所：山东省淄博市周村区新华大道2009号新华医疗科技园E区 E2-1-1#厂房101室 5、生产地址：山东省淄博市周村区新华大道2009号新华医疗科技园E区 E2-1-1#厂房 6、结构及组成：本产品主要由外壳、端盖、透析膜、密封胶与密封塞组成。本产品采用电子束辐照灭 菌，一次性使用。 7、型号、规格：CLEAR 15H，CLEAR 16H，CLE ...

证券日报网讯12月25日，新华医疗（600587）在互动平台回答投资者提问时表示，截至2025年11月25 日，公司控股股东已累计增持386.38万股，增持金额6011.35万元。控股股东将继续根据资本市场整体情 况、公司股价波动及自身资金安排，在合规前提下择机推进后续增持工作。 ...

Core Viewpoint - Xinhua Medical has received medical device registration certificates from the National Medical Products Administration and the Shandong Provincial Medical Products Administration for its products [1] Group 1 - Xinhua Medical announced the receipt of medical device registration certificates for both the company and its wholly-owned subsidiary, Shandong Xinhua Blood Technology Co., Ltd. [1]

证券日报网讯12月25日，新华医疗（600587）在互动平台回答投资者提问时表示，公司实际控制人为山 东省人民政府国有资产监督管理委员会。 ...

Group 1 - Guangdong Construction signed an EPC contract worth 416 million yuan, with a total construction area of 99,595.6 square meters and a construction period of 640 calendar days [1] - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [2] - Jinbei Automotive signed a memorandum of understanding with E-Works to establish a research and development center for electric light commercial vehicles [3] Group 2 - Hongsheng Huayuan is expected to win approximately 569 million yuan in procurement projects from the State Grid, which represents about 5.61% of the company's projected revenue for 2024 [4] - Zhongding Co. plans to establish a joint venture for humanoid robot manufacturing with a registered capital of 50 million yuan [5] - Kede CNC's new factory in Shenyang is expected to achieve an annual production capacity of about 60 units [6] Group 3 - Hongbo Pharmaceutical's share transfer price is set at 25.27 yuan per share [7] - ST Jinglan plans to sign a letter of intent for the acquisition of Xinlian Environmental Technology Co., enhancing its core technology competitiveness [8][9] - Hato Co. announced the resignation of its general manager due to job relocation [10] Group 4 - Meibang Co. plans to apply for a new bank credit line of up to 160 million yuan [11] - Southern Media's general manager resigned due to job relocation [12] - Dalian Electric Porcelain's subsidiary is expected to win procurement projects from the State Grid worth approximately 70.7 million yuan [13] Group 5 - Sinopharm Modern's subsidiary received a drug registration certificate for a new medication [14] - ST Meigu plans to implement a capital reserve transfer to increase share capital, leading to a one-day stock suspension [15] - Ruisheng Intelligent confirmed a transaction of 152 million yuan for domestic computing equipment procurement [16] Group 6 - Jinguang Electric won three procurement packages from the State Grid, totaling 37.43 million yuan [17] - Guangju Energy increased its stake in Mawan Power to 14.42% by acquiring an 8% share for 680 million yuan [18][19] - ST Lingda announced a stock suspension due to capital reserve transfer related to its restructuring plan [20] Group 7 - Suli Co. plans to increase its investment in Suli Ningxia by 76.63 million yuan [21] - Dalian Shengya's subsidiary plans to reduce its registered capital by 32.37 million yuan [22] - Yinxin Technology received a cash dividend of 11.05 million yuan from its subsidiary [23] Group 8 - Haike New Source signed a three-year supply agreement for 270,000 tons of electrolyte materials [24] - Xinhua Medical received registration certificates for several medical devices [25] - Wantai Bio received a registration certificate for an HIV antibody testing kit [26] Group 9 - Beilu Pharmaceutical obtained a drug registration certificate for a new erectile dysfunction treatment [31] - Zhongwei Company is planning to issue shares to acquire assets, leading to a stock suspension [32] - Zhejiang Haideman plans to purchase land for strategic development, with a budget of up to 260 million yuan [33] Group 10 - Ningbo Ocean announced the resignation of its deputy general manager due to job adjustments [34] - Tongguang Cable is expected to win procurement projects from the State Grid worth over 139 million yuan [35]

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-065 山东新华医疗器械股份有限公司 关于公司产品获得三类和二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）及全资 子公司山东新华血液技术有限公司于近日收到国家药品监督管理局和山东省药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 （一）血液透析器 1、产品名称：血液透析器 2、注册证编号：国械注准 20253102637 3、注册人名称：山东新华血液技术有限公司 4、注册人住所：山东省淄博市周村区新华大道 2009 号新华医疗科技园 E 区 E2-1-1#厂房 101 室 5、生产地址：山东省淄博市周村区新华大道 2009 号新华医疗科技园 E 区 E2-1-1#厂房 6、结构及组成：本产品主要由外壳、端盖、透析膜、密封胶与密封塞组成。 本产品采用电子束辐照灭菌，一次性使用。 7、型号、规格：CLEAR 15H，C ...

证券日报网讯12月23日，新华医疗（600587）在互动平台回答投资者提问时表示，公司长期关注脑机接 口技术在康复领域的应用潜力，重点推进该技术与现有运动康复、认知康复设备的产品融合与技术升 级。目前，公司已启动脑机接口与康复设备结合的初代样机研发，未来将进一步拓展其在康复评估与训 练中的实际应用。 ...